You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCandesartan
Accession NumberDB00796  (APRD00420)
TypeSmall Molecule
GroupsApproved
DescriptionCandesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Structure
Thumb
Synonyms
2-Ethoxy-1-(P-(O-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl]}-1H-benzimidazole-7-carboxylic acid
Blopress
Candesartan cilexetil
CV-11974
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-candesartanTablet32 mgOralAccord Healthcare Inc2012-02-16Not applicableCanada
Ach-candesartanTablet4 mgOralAccord Healthcare Inc2012-02-16Not applicableCanada
Ach-candesartanTablet8 mgOralAccord Healthcare Inc2012-02-16Not applicableCanada
Ach-candesartanTablet16 mgOralAccord Healthcare Inc2012-02-16Not applicableCanada
Act CandesartanTablet4 mgOralActavis Pharma Company2011-11-30Not applicableCanada
Act CandesartanTablet8 mgOralActavis Pharma Company2011-11-30Not applicableCanada
Act CandesartanTablet16 mgOralActavis Pharma Company2011-12-15Not applicableCanada
Act CandesartanTablet32 mgOralActavis Pharma Company2011-11-30Not applicableCanada
AtacandTablet4 mg/1OralAstra Zeneca Pharmaceuticals Lp1998-09-14Not applicableUs
AtacandTablet32 mgOralAstrazeneca Canada Inc2008-07-17Not applicableCanada
AtacandTablet16 mg/1OralPhysicians Total Care, Inc.2000-11-21Not applicableUs
AtacandTablet4 mgOralAstrazeneca Canada Inc2005-06-28Not applicableCanada
AtacandTablet8 mg/1OralAstra Zeneca Pharmaceuticals Lp1998-09-14Not applicableUs
AtacandTablet16 mg/1OralCardinal Health2009-11-11Not applicableUs
AtacandTablet16 mg/1OralAstra Zeneca Pharmaceuticals Lp1998-09-14Not applicableUs
AtacandTablet16 mg/1Oralbryant ranch prepack1998-09-14Not applicableUs
AtacandTablet4 mg/1OralCarilion Materials Management1998-09-14Not applicableUs
AtacandTablet32 mg/1OralAstra Zeneca Pharmaceuticals Lp1998-09-14Not applicableUs
AtacandTablet4 mg/1Oralbryant ranch prepack1998-09-14Not applicableUs
AtacandTablet8 mg/1OralCarilion Materials Management1998-09-14Not applicableUs
Atacand Tab 16 mgTablet16 mgOralAstrazeneca Canada Inc1998-12-07Not applicableCanada
Atacand Tab 8mgTablet8 mgOralAstrazeneca Canada Inc1998-12-07Not applicableCanada
Auro-candesartanTablet8 mgOralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-candesartanTablet16 mgOralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-candesartanTablet32 mgOralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-candesartanTablet4 mgOralAuro Pharma Inc2015-12-02Not applicableCanada
Bio-candesartanTablet8 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-candesartanTablet16 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-candesartanTablet32 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-candesartanTablet4 mgOralBiomed PharmaNot applicableNot applicableCanada
CandesartanTablet4 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
CandesartanTablet32 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
CandesartanTablet4 mgOralSanis Health Inc2012-07-20Not applicableCanada
CandesartanTablet8 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
CandesartanTablet4 mgOralSivem Pharmaceuticals Ulc2012-07-11Not applicableCanada
CandesartanTablet8 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
CandesartanTablet8 mgOralPro Doc Limitee2012-02-02Not applicableCanada
CandesartanTablet8 mgOralSanis Health Inc2012-07-20Not applicableCanada
CandesartanTablet32 mgOralPro Doc Limitee2014-06-05Not applicableCanada
CandesartanTablet4 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
CandesartanTablet32 mgOralSanis Health Inc2015-01-12Not applicableCanada
CandesartanTablet8 mgOralSivem Pharmaceuticals Ulc2012-07-11Not applicableCanada
CandesartanTablet16 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
CandesartanTablet16 mgOralPro Doc Limitee2012-02-02Not applicableCanada
CandesartanTablet16 mgOralSanis Health Inc2012-07-20Not applicableCanada
CandesartanTablet16 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
CandesartanTablet16 mgOralSivem Pharmaceuticals Ulc2012-07-11Not applicableCanada
CandesartanTablet32 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Candesartan CilexetilTablet8 mg/1OralAmerican Health Packaging2015-09-01Not applicableUs
Candesartan CilexetilTablet8 mgOralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Candesartan CilexetilTablet4 mg/1OralPar Pharmaceutical Inc.2013-05-21Not applicableUs
Candesartan CilexetilTablet16 mgOralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Candesartan CilexetilTablet16 mg/1OralAmerican Health Packaging2016-09-15Not applicableUs
Candesartan CilexetilTablet32 mg/1OralAmerican Health Packaging2015-09-01Not applicableUs
Candesartan CilexetilTablet8 mg/1OralPar Pharmaceutical Inc.2013-05-21Not applicableUs
Candesartan CilexetilTablet32 mgOralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Candesartan CilexetilTablet16 mg/1OralPar Pharmaceutical Inc.2013-05-21Not applicableUs
Candesartan CilexetilTablet4 mgOralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Candesartan CilexetilTablet32 mg/1OralPar Pharmaceutical Inc.2013-05-21Not applicableUs
Dom-candesartanTablet8 mgOralDominion Pharmacal2013-10-16Not applicableCanada
Dom-candesartanTablet4 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-candesartanTablet16 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-candesartanTablet32 mgOralDominion PharmacalNot applicableNot applicableCanada
Ipg-candesartanTablet32 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-candesartanTablet4 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-candesartanTablet8 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-candesartanTablet16 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-candesartanTablet32 mgOralJamp Pharma Corporation2012-06-11Not applicableCanada
Jamp-candesartanTablet4 mgOralJamp Pharma Corporation2012-06-29Not applicableCanada
Jamp-candesartanTablet8 mgOralJamp Pharma Corporation2012-06-11Not applicableCanada
Jamp-candesartanTablet16 mgOralJamp Pharma Corporation2012-06-11Not applicableCanada
Mylan-candesartanTablet4 mgOralMylan Pharmaceuticals Ulc2012-02-09Not applicableCanada
Mylan-candesartanTablet8 mgOralMylan Pharmaceuticals Ulc2012-02-09Not applicableCanada
Mylan-candesartanTablet16 mgOralMylan Pharmaceuticals Ulc2012-02-09Not applicableCanada
Mylan-candesartanTablet32 mgOralMylan Pharmaceuticals Ulc2012-02-09Not applicableCanada
Ntp-candesartanTablet8 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-candesartanTablet16 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-candesartanTablet32 mgOralTeva Canada LimitedNot applicableNot applicableCanada
PMS-candesartanTablet4 mgOralPharmascience Inc2012-08-06Not applicableCanada
PMS-candesartanTablet8 mgOralPharmascience Inc2012-08-06Not applicableCanada
PMS-candesartanTablet16 mgOralPharmascience Inc2012-08-06Not applicableCanada
PMS-candesartanTablet32 mgOralPharmascience Inc2012-08-06Not applicableCanada
Priva-candesartanTablet8 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-candesartanTablet16 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-candesartanTablet32 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-candesartanTablet4 mgOralPharmapar IncNot applicableNot applicableCanada
Q-candesartanTablet8 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-candesartanTablet32 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-candesartanTablet16 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-candesartanTablet4 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-candesartanTablet32 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-candesartanTablet4 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-candesartanTablet8 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-candesartanTablet16 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Riva-candesartanTablet16 mgOralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-candesartanTablet32 mgOralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-candesartanTablet4 mgOralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-candesartanTablet8 mgOralLaboratoire Riva Inc2014-12-03Not applicableCanada
Sandoz CandesartanTablet16 mgOralSandoz Canada Incorporated2011-04-26Not applicableCanada
Sandoz CandesartanTablet32 mgOralSandoz Canada Incorporated2014-03-19Not applicableCanada
Sandoz CandesartanTablet4 mgOralSandoz Canada Incorporated2011-04-26Not applicableCanada
Sandoz CandesartanTablet32 mgOralSandoz Canada Incorporated2012-11-23Not applicableCanada
Sandoz CandesartanTablet8 mgOralSandoz Canada Incorporated2011-04-26Not applicableCanada
Septa-candesartanTablet32 mgOralSepta Pharmaceuticals IncNot applicableNot applicableCanada
Septa-candesartanTablet16 mgOralSepta Pharmaceuticals IncNot applicableNot applicableCanada
Teva-candesartanTablet8 mgOralTeva Canada Limited2012-06-01Not applicableCanada
Teva-candesartanTablet16 mgOralTeva Canada Limited2012-06-01Not applicableCanada
Teva-candesartanTablet32 mgOralTeva Canada Limited2012-06-01Not applicableCanada
Zinda-candesartanTablet32 mgOralZinda Pharma LimitedNot applicableNot applicableCanada
Zinda-candesartanTablet16 mgOralZinda Pharma LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-candesartanTablet16 mgOralApotex Inc2011-04-26Not applicableCanada
Apo-candesartanTablet32 mgOralApotex Inc2013-07-16Not applicableCanada
Apo-candesartanTablet4 mgOralApotex Inc2011-04-26Not applicableCanada
Apo-candesartanTablet8 mgOralApotex Inc2011-04-26Not applicableCanada
Candesartan CilexetilTablet16 mg/1OralSandoz Inc2013-05-21Not applicableUs
Candesartan CilexetilTablet16 mg/1OralAmerican Health Packaging2015-09-01Not applicableUs
Candesartan CilexetilTablet16 mg/1OralApotex Corp2014-01-13Not applicableUs
Candesartan CilexetilTablet32 mg/1OralSandoz Inc2013-05-21Not applicableUs
Candesartan CilexetilTablet32 mg/1OralApotex Corp2014-01-13Not applicableUs
Candesartan CilexetilTablet4 mg/1OralSandoz Inc2013-05-21Not applicableUs
Candesartan CilexetilTablet4 mg/1OralApotex Corp2014-01-13Not applicableUs
Candesartan CilexetilTablet16 mg/1OralCarilion Materials Management2013-05-21Not applicableUs
Candesartan CilexetilTablet8 mg/1OralSandoz Inc2013-05-21Not applicableUs
Candesartan CilexetilTablet8 mg/1OralApotex Corp2014-01-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AmiasEureco (Netherlands), Takeda (United Kingdom)
BlopressTakeda
Brand mixtures
NameLabellerIngredients
Act Candesartan/hctActavis Pharma Company
Apo-candesartan/hctzApotex Inc
Atacand HctPhysicians Total Care, Inc.
Atacand PlusAstrazeneca Canada Inc
Auro-candesartan HctAuro Pharma Inc
Candesartan Cilexetil and HydrochlorothiazideMylan Pharmaceuticals Inc.
Candesartan Cilexetil and Hydrochlorothiazide TabletsAlembic Pharmaceuticals Limited
Candesartan Cilexetil-hydrochlorothiazidePar Pharmaceutical Inc.
Candesartan HctSivem Pharmaceuticals Ulc
Candesartan-hctzPro Doc Limitee
Candesartan/hctzSanis Health Inc
Ipg-candesartan + HctInternational Pharmaceutical Generics Ltd
Mylan-candesartan HctzMylan Pharmaceuticals Ulc
PMS-candesartan HctzPharmascience Inc
Sandoz Candesartan PlusSandoz Canada Incorporated
Septa-candesartan HctzSepta Pharmaceuticals Inc
Teva-candesartan/hctzTeva Canada Limited
Zinda-candesartan/hydrochlorothiazideZinda Pharma Limited
SaltsNot Available
Categories
UNIIS8Q36MD2XX
CAS number139481-59-7
WeightAverage: 440.454
Monoisotopic: 440.159688536
Chemical FormulaC24H20N6O3
InChI KeyHTQMVQVXFRQIKW-UHFFFAOYSA-N
InChI
InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)
IUPAC Name
2-ethoxy-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid
SMILES
CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Pharmacology
IndicationMay be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Structured Indications
PharmacodynamicsCandesartan cilexetil is an ARB prodrug that is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS. RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.
Mechanism of actionCandesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.
TargetKindPharmacological actionActionsOrganismUniProt ID
Type-1 angiotensin II receptorProteinyes
antagonist
HumanP30556 details
Related Articles
AbsorptionFollowing administration of the candesartan cilexetil prodrug, the absolute bioavailability of candesartan was estimated to be 15%. Food with a high fat content has no affect on the bioavailability of candesartan from candesartan cilexetil.
Volume of distribution
  • 0.13 L/kg
Protein bindingCandesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
Metabolism

The prodrug candesartan cilexetil undergoes rapid and complete ester hydrolysis in the intestinal wall to form the active drug, candesartan. Elimination of candesartan is primarily as unchanged drug in the urine and, by the biliary route, in the feces. Minor hepatic metabolism of candesartan (<20%)occurs by O-deethylation via cytochrome P450 2C9 to form an inactive metabolite. Candesartan undergoes N-glucuronidation in the tetrazole ring by uridine diphosphate glucuronosyltransferase 1A3 (UGT1A3). O-glucuronidation may also occur. 75% of candesartan is excreted as unchanged drug in urine and feces.

SubstrateEnzymesProduct
Candesartan
O-Deethylated candesartanDetails
Candesartan
Candesartan N2-glucuronideDetails
Candesartan
Candesartan O-glucuronideDetails
Route of eliminationWhen candesartan is administered orally, about 26% of the dose is excreted unchanged in urine. Candesartan is mainly excreted unchanged in urine and feces (via bile).
Half lifeApproximately 9 hours.
Clearance
  • 0.37 mL/min/kg
ToxicityNo lethality was observed in acute toxicity studies in mice, rats and dogs given single oral doses of up to 2000 mg/kg of candesartan cilexetil or in rats given single oral doses of up to 2000 mg/kg of candesartan cilexetil in combination with 1000 mg/kg of hydrochlorothiazide. In mice given single oral doses of the primary metabolite, candesartan, the minimum lethal dose was greater than 1000 mg/kg but less than 2000 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Candesartan Action PathwayDrug actionSMP00158
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Candesartan.Experimental
AbirateroneThe metabolism of Candesartan can be decreased when combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Candesartan is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Aceclofenac.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Candesartan.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Candesartan is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Candesartan is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Candesartan.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Candesartan is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Candesartan.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Candesartan.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Candesartan.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Candesartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Candesartan.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Candesartan.Approved, Investigational
AlprenololCandesartan may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Candesartan.Approved, Investigational
AmifostineCandesartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Candesartan.Approved
AmiodaroneThe metabolism of Candesartan can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Candesartan.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Candesartan.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Candesartan.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Candesartan.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Candesartan is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Candesartan is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Candesartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Candesartan is combined with Antipyrine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Candesartan.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Candesartan is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Candesartan is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Candesartan is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Candesartan can be increased when combined with Aprepitant.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Candesartan.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Candesartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Candesartan is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Candesartan.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Candesartan.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Candesartan.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Candesartan.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Candesartan is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Candesartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Candesartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Candesartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Candesartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Candesartan is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Candesartan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Candesartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Candesartan.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Benoxaprofen.Withdrawn
BepridilCandesartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Candesartan.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Candesartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Candesartan.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Candesartan is combined with Betulinic Acid.Investigational
BimatoprostCandesartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Candesartan.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Candesartan.Approved
BortezomibThe risk or severity of adverse effects can be increased when Candesartan is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Candesartan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Candesartan.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Candesartan.Approved
BretyliumThe risk or severity of adverse effects can be increased when Candesartan is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Candesartan.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Candesartan.Approved
BromfenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Candesartan.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Candesartan is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Candesartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Candesartan is combined with Bupivacaine.Approved, Investigational
BupranololCandesartan may increase the hypotensive activities of Bupranolol.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Candesartan.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Candesartan.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Candesartan.Experimental
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Candesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candesartan is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Candesartan can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Captopril.Approved
CarbamazepineThe metabolism of Candesartan can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Candesartan is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Candesartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Candesartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Candesartan.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Candesartan is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Candesartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Celecoxib.Approved, Investigational
CeliprololCandesartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Candesartan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Candesartan.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Candesartan.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Candesartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Candesartan is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Candesartan.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Candesartan.Approved
CholecalciferolThe metabolism of Candesartan can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Candesartan is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Candesartan.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Candesartan.Approved, Investigational
CiprofloxacinCandesartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Candesartan.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Candesartan.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Candesartan.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Candesartan is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Candesartan.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Candesartan is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Candesartan.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Candesartan is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Candesartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Candesartan is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Candesartan.Approved, Nutraceutical
ClotrimazoleThe metabolism of Candesartan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Candesartan.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Candesartan.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Candesartan.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Candesartan is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Candesartan.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Candesartan.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Candesartan.Approved
CurcuminThe risk or severity of adverse effects can be increased when Candesartan is combined with Curcumin.Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Candesartan.Approved, Investigational, Vet Approved
CyclosporineCandesartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Candesartan.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Candesartan is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Candesartan.Approved
DabrafenibThe serum concentration of Candesartan can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Candesartan.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Candesartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Candesartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Candesartan.Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Candesartan.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Candesartan.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Candesartan.Approved
DelavirdineThe metabolism of Candesartan can be decreased when combined with Delavirdine.Approved
DeserpidineCandesartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Candesartan is combined with Desflurane.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Candesartan.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Candesartan.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Candesartan.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Candesartan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Candesartan is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Candesartan.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Candesartan is combined with Diflunisal.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Candesartan.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Candesartan.Approved
DihydralazineCandesartan may increase the hypotensive activities of Dihydralazine.Investigational
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Candesartan.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Candesartan.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Candesartan is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Candesartan is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Candesartan.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Candesartan.Approved, Investigational, Vet Approved
DorzolamideCandesartan may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Candesartan.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Candesartan.Approved, Investigational
DrospirenoneCandesartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Droxicam.Approved
DuloxetineCandesartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Candesartan is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Candesartan is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Candesartan is combined with Ebselen.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Candesartan.Approved
EfavirenzThe metabolism of Candesartan can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineCandesartan may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Candesartan.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Candesartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Candesartan is combined with Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Candesartan.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Candesartan.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Candesartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Candesartan.Approved
EpoprostenolCandesartan may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Eprosartan.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Candesartan.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Candesartan.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Candesartan.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Candesartan.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Candesartan.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Candesartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Candesartan is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Candesartan.Approved
EtodolacThe risk or severity of adverse effects can be increased when Candesartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Candesartan is combined with Etofenamate.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Candesartan.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Candesartan can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Candesartan is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Candesartan.Approved
exisulindThe risk or severity of adverse effects can be increased when Candesartan is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Candesartan.Approved
FelodipineThe risk or severity of adverse effects can be increased when Candesartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Candesartan is combined with Fenbufen.Approved
FenoldopamCandesartan may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Fenoprofen.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Candesartan.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Candesartan.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Candesartan.Approved
FimasartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Candesartan is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Candesartan can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Candesartan can be decreased when combined with Fluconazole.Approved
FlunixinThe risk or severity of adverse effects can be increased when Candesartan is combined with Flunixin.Vet Approved
FluorouracilThe metabolism of Candesartan can be decreased when combined with Fluorouracil.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Candesartan.Approved
FluvastatinThe metabolism of Candesartan can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Candesartan can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Candesartan can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Candesartan.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Candesartan.Approved, Vet Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Candesartan.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Candesartan.Approved
GemfibrozilThe metabolism of Candesartan can be decreased when combined with Gemfibrozil.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Candesartan.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Candesartan.Withdrawn
GuanabenzGuanabenz may increase the hypotensive activities of Candesartan.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Candesartan.Approved
GuanethidineCandesartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Candesartan is combined with Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Candesartan.Approved
HalothaneThe risk or severity of adverse effects can be increased when Candesartan is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Candesartan.Approved, Investigational
HexamethoniumCandesartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Candesartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Candesartan is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Candesartan is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Candesartan.Approved
HydralazineThe risk or severity of adverse effects can be increased when Candesartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Candesartan is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Candesartan.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Candesartan.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Candesartan.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Candesartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Candesartan is combined with Icatibant.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Candesartan.Approved
IloprostIloprost may increase the hypotensive activities of Candesartan.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Candesartan.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Candesartan.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Candesartan.Approved
IndapamideThe risk or severity of adverse effects can be increased when Candesartan is combined with Indapamide.Approved
IndenololCandesartan may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Candesartan.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Candesartan.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Indoprofen.Withdrawn
IndoraminCandesartan may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Candesartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Candesartan.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Candesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Candesartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Candesartan is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Candesartan is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Candesartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Candesartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Candesartan.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Candesartan.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Kebuzone.Experimental
KetanserinCandesartan may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Candesartan.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Candesartan.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Candesartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Candesartan.Approved
LacidipineCandesartan may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Candesartan.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Candesartan.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Candesartan.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Candesartan.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Candesartan.Approved
LeflunomideThe metabolism of Candesartan can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Candesartan.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Candesartan.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Candesartan.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Candesartan.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Candesartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Candesartan is combined with Levobupivacaine.Approved
LevodopaCandesartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Candesartan.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Candesartan.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Candesartan is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Candesartan.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Candesartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Candesartan.Approved
LofexidineCandesartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Candesartan.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Candesartan.Approved
LovastatinThe metabolism of Candesartan can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Loxoprofen.Approved
LumacaftorThe serum concentration of Candesartan can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Lumiracoxib.Approved, Investigational
MacitentanCandesartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Candesartan is combined with Magnesium salicylate.Approved
ManidipineCandesartan may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Candesartan.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Candesartan is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Candesartan.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Candesartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Candesartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Candesartan is combined with Metamizole.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Candesartan.Approved
MethohexitalMethohexital may increase the hypotensive activities of Candesartan.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Candesartan.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Candesartan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Candesartan is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Candesartan.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Candesartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Candesartan.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Candesartan.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Candesartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Candesartan.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Candesartan.Approved, Investigational
MetyrosineCandesartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilCandesartan may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Candesartan.Approved, Illicit
MifepristoneThe serum concentration of Candesartan can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Candesartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Candesartan.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Candesartan.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Candesartan.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Candesartan is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Candesartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Candesartan.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Candesartan.Approved, Investigational
MoxonidineCandesartan may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Candesartan.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Candesartan is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Candesartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Candesartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Candesartan is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Candesartan is combined with Naftifine.Approved
NaftopidilCandesartan may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Candesartan.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Candesartan.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Candesartan is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Candesartan is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Candesartan is combined with Nebivolol.Approved, Investigational
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Candesartan.Approved
NepafenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Candesartan is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Candesartan.Withdrawn
NicardipineThe metabolism of Candesartan can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Candesartan.Approved
NifedipineThe risk or severity of adverse effects can be increased when Candesartan is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Candesartan is combined with Niflumic Acid.Approved
NiguldipineCandesartan may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Candesartan.Approved, Investigational
NilvadipineCandesartan may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Candesartan is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Candesartan.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Candesartan.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Candesartan.Approved
NitrendipineCandesartan may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Candesartan is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Candesartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Candesartan.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Candesartan.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Candesartan.Approved
ObinutuzumabCandesartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Candesartan.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Candesartan.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Candesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Candesartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Candesartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Candesartan is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Candesartan.Approved
OmeprazoleThe metabolism of Candesartan can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Candesartan is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Candesartan.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Candesartan is combined with Oxaprozin.Approved
OxprenololCandesartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Candesartan.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Candesartan.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Candesartan is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Candesartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Candesartan.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Candesartan.Approved
PenbutololThe risk or severity of adverse effects can be increased when Candesartan is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Candesartan.Approved, Vet Approved
PentoliniumCandesartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Candesartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Candesartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Candesartan.Withdrawn
PhenobarbitalThe metabolism of Candesartan can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineCandesartan may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Candesartan.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Candesartan.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Candesartan can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Candesartan is combined with Pimecrolimus.Approved, Investigational
PinacidilCandesartan may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Candesartan is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Pipamperone.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Candesartan.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Piroxicam.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Candesartan.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Candesartan.Withdrawn
PolythiazideCandesartan may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Candesartan.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Candesartan.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Candesartan is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Candesartan.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Candesartan.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Candesartan.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Candesartan.Approved, Vet Approved
PrimidoneThe metabolism of Candesartan can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Candesartan.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Candesartan is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Candesartan is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Candesartan.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Candesartan.Approved
PTC299The risk or severity of adverse effects can be increased when Candesartan is combined with PTC299.Investigational
PyrimethamineThe metabolism of Candesartan can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Candesartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Candesartan.Approved
QuinineQuinine may increase the hypotensive activities of Candesartan.Approved
RamiprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Candesartan.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Candesartan.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Candesartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Candesartan is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Candesartan.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Candesartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Candesartan.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Candesartan is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Candesartan.Approved
RifampicinThe metabolism of Candesartan can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Candesartan can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Candesartan.Approved, Investigational
RilmenidineCandesartan may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Candesartan is combined with Riociguat.Approved
RisperidoneCandesartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Candesartan.Approved, Investigational
RituximabCandesartan may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Candesartan.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Rofecoxib.Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Candesartan.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Candesartan is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Candesartan is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Candesartan is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Candesartan is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Candesartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Candesartan is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Candesartan.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Candesartan is combined with Salsalate.Approved
SaprisartanCandesartan may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Candesartan.Approved, Investigational
SecobarbitalThe metabolism of Candesartan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Candesartan.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Candesartan.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Candesartan is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Candesartan is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Candesartan.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Candesartan.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Candesartan.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Candesartan.Approved, Investigational
SitaxentanCandesartan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Candesartan is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Candesartan.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Candesartan.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Candesartan.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Candesartan.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Candesartan.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Candesartan.Approved
SRT501The risk or severity of adverse effects can be increased when Candesartan is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Candesartan is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Candesartan is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Candesartan can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Candesartan can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Candesartan is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Candesartan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Candesartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Suprofen.Approved, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Candesartan.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Candesartan.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Candesartan.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Candesartan is combined with Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Candesartan.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Candesartan.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Candesartan.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Candesartan.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Candesartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Candesartan is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Candesartan is combined with Teriflunomide.Approved
TerlipressinCandesartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Candesartan is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Candesartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Candesartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Candesartan is combined with Thioridazine.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Tiaprofenic acid.Approved
TiboloneCandesartan may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Candesartan.Approved
TiclopidineThe metabolism of Candesartan can be decreased when combined with Ticlopidine.Approved
TicrynafenCandesartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Candesartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Candesartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Candesartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Candesartan.Approved
TolazolineCandesartan may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Candesartan can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Candesartan.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Candesartan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Candesartan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Candesartan.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Candesartan.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Candesartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Candesartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Candesartan.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Candesartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Candesartan.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Candesartan.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Candesartan is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Candesartan.Approved
TrichlormethiazideCandesartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinCandesartan may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanCandesartan may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Candesartan.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Candesartan is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Candesartan.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Candesartan.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Candesartan.Approved
UnoprostoneCandesartan may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Candesartan can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Candesartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Candesartan.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Candesartan.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Candesartan.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Candesartan.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Candesartan.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Candesartan.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Candesartan.Approved, Investigational
VinpocetineCandesartan may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Candesartan.Approved
VoriconazoleThe metabolism of Candesartan can be decreased when combined with Voriconazole.Approved, Investigational
XylometazolineCandesartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Candesartan.Approved, Vet Approved
ZafirlukastThe metabolism of Candesartan can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Candesartan.Approved
ZileutonThe risk or severity of adverse effects can be increased when Candesartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Candesartan is combined with Zomepirac.Withdrawn
Food Interactions
  • Administer on a regular basis, at about the same time each day.
  • Take without regard to meals.
References
Synthesis Reference

Marina Etinger, Boris Fedotev, Ben-Zion Dolitzky, “Preparation of candesartan cilexetil.” U.S. Patent US20050131037, issued June 16, 2005.

US20050131037
General References
  1. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6;362(9386):759-66. [PubMed:13678868 ]
  2. Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197. [PubMed:19563275 ]
  3. Baguet JP, Barone-Rochette G, Neuder Y: Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. [PubMed:19436650 ]
  4. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660 ]
  5. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328 ]
External Links
ATC CodesC09CA06C09DB07C09DA06
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (49.4 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8717
Caco-2 permeable-0.6208
P-glycoprotein substrateSubstrate0.5186
P-glycoprotein inhibitor INon-inhibitor0.848
P-glycoprotein inhibitor IINon-inhibitor0.9115
Renal organic cation transporterNon-inhibitor0.8266
CYP450 2C9 substrateNon-substrate0.7397
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6504
CYP450 1A2 substrateInhibitor0.5594
CYP450 2C9 inhibitorInhibitor0.5195
CYP450 2D6 inhibitorNon-inhibitor0.889
CYP450 2C19 inhibitorInhibitor0.5151
CYP450 3A4 inhibitorInhibitor0.7392
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7895
Ames testAMES toxic0.556
CarcinogenicityNon-carcinogens0.7561
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.5515 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.794
hERG inhibition (predictor II)Non-inhibitor0.5837
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Astrazeneca pharmaceuticals lp
Packagers
Dosage forms
FormRouteStrength
TabletOral16 mg/1
TabletOral32 mg
TabletOral32 mg/1
TabletOral4 mg
TabletOral4 mg/1
TabletOral8 mg/1
TabletOral16 mg
TabletOral8 mg
TabletOral
Prices
Unit descriptionCostUnit
Atacand 30 4 mg tablet Bottle75.98USD bottle
Atacand 30 8 mg tablet Bottle74.96USD bottle
Atacand hct 32-25 mg tablet3.64USD tablet
Atacand hct 32-12.5 mg tablet3.43USD tablet
Atacand 32 mg tablet3.36USD tablet
Atacand hct 16-12.5 mg tablet3.36USD tablet
Atacand 16 mg tablet2.49USD tablet
Atacand 4 mg tablet2.44USD tablet
Atacand 8 mg tablet2.44USD tablet
Atacand 16 mg Tablet1.28USD tablet
Atacand 32 mg Tablet1.28USD tablet
Atacand 8 mg Tablet1.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2040955 No1998-02-032011-04-22Canada
CA2083305 No2003-12-092012-11-19Canada
US5534534 No1994-01-092014-01-09Us
US5705517 No1994-04-182011-04-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP6.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00771 mg/mLALOGPS
logP4.02ALOGPS
logP5.05ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)2.97ChemAxon
pKa (Strongest Basic)1.71ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area118.81 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity134.92 m3·mol-1ChemAxon
Polarizability45.35 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTetrazoles
Direct ParentBiphenyltetrazoles and derivatives
Alternative Parents
Substituents
  • Biphenyltetrazole
  • Biphenyl
  • Benzimidazole
  • Phenylmethylamine
  • Benzoyl
  • Alkyl aryl ether
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous amide
  • Imidazole
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Cervenka L, Navar LG: Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan. J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S197-201. [PubMed:9892163 ]
  3. Malmqvist K, Kahan T, Dahl M: Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens. 2000 May;13(5 Pt 1):504-11. [PubMed:10826401 ]
  4. Wada T, Inada Y, Ojima M, Sanada T, Shibouta Y, Nishikawa K: Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats. Hypertens Res. 1996 Jun;19(2):75-81. [PubMed:10968199 ]
  5. Engelhorn T, Doerfler A, Heusch G, Schulz R: Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats. Neurosci Lett. 2006 Oct 2;406(1-2):92-6. Epub 2006 Aug 9. [PubMed:16901636 ]
  6. Caballero-George C, Vanderheyden PM, Solis PN, Gupta MP, Pieters L, Vauquelin G, Vlietinck A: In vitro effect of sanguinarine alkaloid on binding of [3H]candesartan to the human angiotensin AT1 receptor. Eur J Pharmacol. 2003 Jan 5;458(3):257-62. [PubMed:12504781 ]
  7. McInnes GT, O'Kane KP, Istad H, Keinanen-Kiukaanniemi S, Van Mierlo HF: Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens. 2000 Apr;14(4):263-9. [PubMed:10805052 ]
  8. Vauquelin G, Fierens F, Van Liefde I: Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens Suppl. 2006 Mar;24(1):S23-30. [PubMed:16601569 ]
  9. Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197. [PubMed:19563275 ]
  10. Meredith PA: Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. Curr Med Res Opin. 2007 Jul;23(7):1693-705. [PubMed:17588300 ]
  11. Baguet JP, Barone-Rochette G, Neuder Y: Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. [PubMed:19436650 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. McClellan KJ, Goa KL: Candesartan cilexetil. A review of its use in essential hypertension. Drugs. 1998 Nov;56(5):847-69. [PubMed:9829158 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23